Concepedia

Yoshito Nakanishi

YN

Statistics

Publications

13

Citations

511

H-Index

13

Active since

2009

Affiliations

The University of Tokyo(Current)

Chugai Pharma (United States)

Yoshito Nakanishi is an author at The University of Tokyo specializing in oncology, life sciences, and medicine.

Publications per year

2009–2018

13

Publications

13

The Fibroblast Growth Factor Receptor Genetic Status as a Potential Predictor of the Sensitivity to CH5183284/Debio 1347, a Novel Selective FGFR Inhibitor

Yoshito Nakanishi, Nukinori Akiyama, Toshiyuki Tsukaguchi et al. · Molecular Cancer Therapeutics · 2014 · 120 citations · Full text

, , +15

Activating Mutations in <i>PIK3CB</i> Confer Resistance to PI3K Inhibition and Define a Novel Oncogenic Role for p110β

Yoshito Nakanishi, Kimberly Walter, Jill M. Spoerke et al. · Cancer Research · 2016 · 66 citations

, , +16

Mechanism of Oncogenic Signal Activation by the Novel Fusion Kinase FGFR3–BAIAP2L1

Yoshito Nakanishi, Nukinori Akiyama, Toshiyuki Tsukaguchi et al. · Molecular Cancer Therapeutics · 2015 · 61 citations · Full text

, , +17

Functional analysis and subcellular location of two flavohemoglobins from Aspergillus oryzae

Shengmin Zhou, Shinya Fushinobu, Sang-Wan Kim et al. · Fungal Genetics and Biology · 2010 · 37 citations

, , +16

Discovery of [5-Amino-1-(2-methyl-3<i>H</i>-benzimidazol-5-yl)pyrazol-4-yl]-(1<i>H</i>-indol-2-yl)methanone (CH5183284/Debio 1347), An Orally Available and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor

Hirosato Ebiike, Naoki Taka, Masayuki Matsushita et al. · Journal of Medicinal Chemistry · 2016 · 37 citations · Full text

, , +16

1–5 of 13